AlphaValue Corporate Services
This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things are getting going...hopefully in FY25
Target
Upside 345%
Price (€) 1.53
Market Cap (€M) 68.5
Perf. 1W: -6.27%
Perf. 1M: -14.7%
Perf. 3M: 14.0%
Perf Ytd: -30.0%
10 day relative perf. to stoxx600: -12.7%
20 day relative perf. to stoxx600: -13.8%
EPS change07/10/2024 16:23

H1 24: not yet meaningful

Change in EPS2024 : € -0.24 vs -0.12ns
2025 : € 0.02 vs 0.02

We have fine-tuned our forecasts for the current year. This plays a very minor role for Crossject since the story is that of the future market launches of the company’s NTEs (New Therapeutic Entities) as from FY25 and has no impact on our valuation. For the sake of detailing, the main difference with our previous FY24e EPS lies in a likely lower level of capitalised production than we expected for the full year, again with no consequences on the rest of our model.



Updates

21 May 25 Financing issue
Another capital increase in the pipe…

07 May 25 Earnings/sales releases
Back to life?

30 Mar 25 EPS change
Integrating the FY24 numbers.

27 Mar 25 Earnings/sales releases
FY24 and outlook: long is the road…

07 Oct 24 EPS change
H1 24: not yet meaningful

25 Sep 24 Earnings/sales releases
H1 24: no real surprise, but a glimpse of disapp...

17 Jul 24 Target Change
We are still believers

.